Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Combination of Lamivudine and Adefovir Dipivoxil for Chronic Hepatitis B
NCT00023309Phase 2Completed
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases
- Start
- Aug 2001
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of adefovir dipivoxil in Chronic Hepatitis B (CHB) (2 arms), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases. Primary endpoint: Maintained Combined Response (Virological, Biochemical and Histological Response) at 196 weeks. Started Aug 2001; status: completed.
02
Drugs
adefovir dipivoxil
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00023309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00023309.